How Regulatory CD25+CD4+ T Cells Impinge on Tumor Immunobiology: The Differential Response of Tumors to Therapies
暂无分享,去创建一个
Jorge Carneiro | Karina Garcia | Kalet Leon | J. Carneiro | K. Leon | A. Lage | Agustin Lage | K. García
[1] R. Schreiber,et al. Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells , 2005, The Journal of experimental medicine.
[2] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[3] K. Knutson,et al. Cancer Immunol Immunother DOI 10.1007/s00262-006-0194-y REVIEW , 2006 .
[4] Lisette G de Pillis,et al. A validated mathematical model of cell-mediated immune response to tumor growth. , 2007, Cancer research.
[5] A. Potti,et al. Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future , 2006, Expert opinion on biological therapy.
[6] T. Fujita,et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.
[7] A. Radunskaya,et al. Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .
[8] Hailing Lu,et al. IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in neu-Transgenic Mice1 , 2006, The Journal of Immunology.
[9] H. Fujii,et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers , 2006, Cancer Immunology, Immunotherapy.
[10] K. Eguchi,et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. , 2006, Oncology reports.
[11] B. Chauffert,et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.
[12] C. Drake,et al. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. , 2006, Blood.
[13] Mark A J Chaplain,et al. Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. , 2004, Mathematical medicine and biology : a journal of the IMA.
[14] A. Houghton,et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self , 2006, Nature Medicine.
[15] T. Elliott,et al. The influence of CD25+ cells on the generation of immunity to tumour cell lines in mice. , 2004, Novartis Foundation symposium.
[16] Dominik Wodarz,et al. A dynamical perspective of CTL cross-priming and regulation: implications for cancer immunology. , 2003, Immunology letters.
[17] M. Beyer,et al. Regulatory T cells in cancer. , 2006, Blood.
[18] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[19] H. Ikeda,et al. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Abdullah,et al. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. , 2006, Immunology letters.
[21] C. June,et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma , 2005, Cancer biology & therapy.
[22] E. Tartour,et al. Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers , 2006, Clinical Cancer Research.
[23] H. Frieboes,et al. An integrated computational/experimental model of tumor invasion. , 2006, Cancer research.
[24] S. Sakaguchi,et al. Regulatory T cells in immune surveillance and treatment of cancer. , 2006, Seminars in cancer biology.
[25] Azuma Ohuchi,et al. A Mathematical Analysis of the Interactions between Immunogenic Tumor Cells and Cytotoxic T Lymphocytes , 2001, Microbiology and immunology.
[26] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[27] Jorge Carneiro,et al. Three-Cell Interactions in T Cell-Mediated Suppression? A Mathematical Analysis of Its Quantitative Implications1 , 2001, The Journal of Immunology.
[28] Hiroshi Tanaka,et al. Depletion of CD4+CD25+ Regulatory Cells Augments the Generation of Specific Immune T Cells in Tumor-Draining Lymph Nodes , 2002, Journal of immunotherapy.
[29] H. Fiegl,et al. The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer , 2005, Clinical Cancer Research.
[30] K. L. Monzón. A quantitative approach to dominant tolerance , 2002 .
[31] J. Chin,et al. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer. , 2006, The Canadian journal of urology.
[32] C. van den Dool,et al. When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+ T cells , 2007, Immunological reviews.
[33] Jorge Carneiro,et al. How regulatory CD25(+)CD4(+) T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors. , 2007, Journal of theoretical biology.
[34] 鬼塚 正三郎. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody , 1999 .
[35] Weiguo Lu,et al. Proportion of CD4+CD25+ Regulatory T Cell is Increased in the Patients with Ovarian Carcinoma , 2005, Cancer investigation.
[36] H. Mellstedt,et al. Clinical results of vaccine therapy for cancer: learning from history for improving the future. , 2006, Advances in cancer research.
[37] Zvia Agur,et al. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. , 2006, Cancer research.
[38] N. Egilmez,et al. Chronic Immune Therapy Induces a Progressive Increase in Intratumoral T Suppressor Activity and a Concurrent Loss of Tumor-Specific CD8+ T Effectors in her-2/neu Transgenic Mice Bearing Advanced Spontaneous Tumors1 , 2006, The Journal of Immunology.
[39] E. Gilboa,et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.
[40] J. Carneiro,et al. Modelling T-cell-mediated suppression dependent on interactions in multicellular conjugates. , 2000, Journal of theoretical biology.
[41] K. Matsushima,et al. Visualization of naturally occurring Foxp3+ regulatory T cells in normal and tumor-bearing mice. , 2004, International immunopharmacology.
[42] Benedetto Piccoli,et al. Optimal Control in a Model of Dendritic Cell Transfection Cancer Immunotherapy , 2006, 2004 43rd IEEE Conference on Decision and Control (CDC) (IEEE Cat. No.04CH37601).
[43] C. June,et al. Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.
[44] S. Fox,et al. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia‐inducible factor (HIF)‐2α but not HIF‐1α , 2007, The Prostate.
[45] B. Moss,et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[46] Youjin Lee,et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors , 2005, The Journal of experimental medicine.
[47] L. Old,et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[48] P. Watson,et al. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. , 2007, Cancer research.
[49] S. Kim-Schulze,et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.